Cervical, head and neck, and prostate cancer Cancer
Conditions
Interventions
A web-based artificial intelligence (AI) auto-planning tool
The CT scan taken at the time of treatment planning is uploaded to a web server called the Radiotherapy planning assistant which automates
Sponsors
University College London
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 17/07/2025: 1. Patients with: 1.1. Histologically confirmed head and neck cancers of the oropharynx, larynx, hypopharynx, and nasopharynx (American Joint Committee on Cancer [AJCC] Stage I-IVB) that have given consent for radical radiotherapy (with or without concurrent chemotherapy). Patients can be included if they have had induction chemotherapy prior to radiotherapy OR 1.2. Histologically confirmed primary cervical cancer (International Federation of Gynaecology and Obstetrics [FIGO]/AJCC Stage IB-IIIC1) that have given consent for radical radiotherapy (with or without concurrent chemotherapy). Patients can be included if they have had induction chemotherapy prior to radiotherapy. OR 1.3. Histologically confirmed primary prostate cancer (AJCC Stage I-IIIC) that have given consent for radical radiotherapy. Patients can be included if they have had prior chemotherapy or are taking a hormonal therapy for their prostate cancer. 2. Provide signed informed consent to participate in the study 3. Aged =18 years _____ Previous inclusion criteria as of 22/05/2024: 1. Patients with: 1.1. Histologically confirmed head and neck cancers of the oropharynx, larynx, hypopharynx, and nasopharynx (American Joint Committee on Cancer [AJCC] Stage I-IVB) that have given consent for radical radiotherapy. Patients can be included if they have had induction chemotherapy prior to radiotherapy OR 1.2. Histologically confirmed primary cervical cancer (International Federation of Gynaecology and Obstetrics [FIGO]/AJCC Stage IB-IIIC1) that have given consent for radical radiotherapy OR 1.3. Histologically confirmed primary prostate cancer (AJCC Stage I-IIIC) that have given consent for radical radiotherapy 2. Provide signed informed consent to participate in the study 3. Aged =18 years _____ Previous inclusion criteria: 1. Consecutive patients at each participating centre with histologically confirmed head and neck cancers of the oropharynx, larynx, hypopharynx and nasopharynx (Stage I-III) that have given consent for primary curative radiotherapy 2. Consecutive histologically confirmed primary cervical cancer patients (Stage IB-IIIB including pelvic node positive) that have given consent for radical radiotherapy 3. Patients aged over 18 years 4. Written informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Current exclusion criteria as of 17/07/2025: 1. Patients requiring radiotherapy after curative surgery or surgery that is intended to remove as much of the tumour as possible 2. Patients receiving a palliative dose of radiotherapy 3. Patients that have any metal implants within the treatment field e.g. hip prostheses. Dental implants are acceptable. _____ Previous exclusion criteria as of 22/05/2024: 1. Patients requiring radiotherapy after curative surgery or surgery that is intended to remove as much of the tumour as possible 2. Patients receiving palliative radiotherapy _____ Previous exclusion criteria: 1. Patients requiring radiotherapy after curative or de-bulking surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 17/07/2025: Overall acceptability of the automated treatment plan. This is a composite outcome including both the assessment of the delineated clinical target volumes (CTVs) and organs-at-risk (OARs) with reference to internationally accepted contouring guidelines and the adherence to pre-defined dosimetric constraints for each tumour type. Timepoint: clinical peer review. _____ Previous primary outcome measure: Overall acceptability of the automated treatment plan. This is a composite outcome including both the assessment of the delineated clinical target volumes (CTVs) and organs-at-risk (OARs) using a pre-defined scale and the adherence to acceptable dosimetric constraints for each tumour type. Timepoint: clinical peer review. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Time and resource savings measured during manual and automated processes: 1.1. Date/time CT planning scan performed 1.2. Date/time of delineation started/completed (grade and number of staff members) 1.3. Date/time of radiotherapy treatment planning completed (grade and number of staff members involved) 1.4. Date/time CT (with gross tumor volume [GTV] contoured manually) sent for autcontouring and planning 1.5. Date/time autocontouring and planning completed 2. Cost-effectiveness measured using time-driven activity-based costing tool based on timing and resource use inputs Timepoint: clinical peer review | — |
Countries
India, Jordan, Malaysia, South Africa
Outcome results
None listed